Table 4. Uni- and multivariate Cox cause-specific hazards analysis of pRCC, ccRCC, and pRCC subtypes (type 1 and type 2) and clinical and pathological variables for the prediction of cancer-specific mortality in patients with metastatic RCC in the post tyrosine kinase inhibitor era.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p | HR | 95%CI | p | |
| Patients with metastatic disease (M1) | ||||||
| Age | 1 | 0.98–1.02 | 0.916 | 1* | 0.98–1.02 | 0.891 |
| Sex (Female vs. Male) | 1.06 | 0.67–1.7 | 0.796 | 1.06* | 0.66–1.71 | 0.815 |
| pT (pT 3–4 vs. pT 1–2) | 1.31 | 0.84–2.04 | 0.237 | 1.21* | 0.76–1.92 | 0.421 |
| Grade (G 3–4 vs. G 1–2) | 1.41 | 0.91–2.2 | 0.125 | 1.36* | 0.86–2.16 | 0.187 |
| pRCC vs. ccRCC | 0.89 | 0.58–1.36 | 0.579 | 0.86 | 0.56–1.34 | 0.514 |
| pRCC type 2 vs. type1 | 5.12 | 1.17–22.31 | 0.03 | 4.63 | 1.05–20.52 | 0.044 |
| pRCC type 1 vs. ccRCC | 0.24 | 0.06–1.02 | 0.053 | 0.29 | 0.07–1.21 | 0.09 |
| pRCC type 2 vs. ccRCC | 1.27 | 0.7–2.27 | 0.431 | 1.34 | 0.74–2.42 | 0.33 |
* HRs are based on two different Cox models and therefore might slightly differ